Regulatoriskt pressmeddelande

Circio Holding ASA – Bond conversion and additional trading restrictions

Reference is made to Circio Holding ASA's (the "Company") outstanding convertible bonds issued to Atlas Special Opportunities, LLC and Atlas Capital Markets, LLC ("Atlas") under the Investment Agreement entered into between Atlas and the Company in March 2023.

Following Circio´s recent release of strong data at the ESGCT Annual Meeting 2025 (link to press release) and subsequent positive impact on the trading in Circio shares, Atlas has requested conversion of bonds with an aggregate nominal value of NOK 14,500,000. This represents all of the current outstanding convertible bonds held by Atlas.

To demonstrate their confidence in the continued positive development of Circio, going forward Atlas has committed to a conservative trading strategy, including reducing the trading limitation in the Investment Agreement from the current 35% down to 15% of the total trading volume and to not exceed 10% on low volume days.

Pursuant to the terms of the agreement, the bonds are converted into 24,006,622 new shares in the Company at a conversion price of NOK 0.604. Accordingly, the Company's share capital will be increased by NOK 14,403,973.20 through the issuance of 24,006,622 new shares upon registration of the share capital increase in the Norwegian Register of Business Enterprises (Nw.: Foretaksregisteret).

Following completion and registration of the bond conversion, the Company's total share capital will amount to NOK 86,175,445.20, divided into 143,625,742 shares, each with a nominal value of NOK 0.60 (including the conversions announced by the Company on 6, 15 and 17 October).

About Circio
Building circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing powerful circular RNA vector expression technology for next generation nucleic acid medicine.

Circio has established a unique circular RNA (circRNA) vector expression technology for next generation RNA, DNA and viral therapeutics. The proprietary circVec platform is based on a modular genetic construct designed for efficient biogenesis of multifunctional circRNA inside target cells. The circVec platform has applications in multiple therapeutic settings, including genetic medicine, cell therapy and chronic disease. It has demonstrated 75-fold increased RNA half-life and up to 40-fold enhanced protein expression vs. conventional mRNA-based viral and non-viral vector systems, with the potential to become a new gold-standard gene expression technology. The circVec R&D activities are being conducted by the wholly owned subsidiary Circio AB in Stockholm, Sweden.

In parallel, Circio is continuing to develop its legacy immuno-oncology program, TG01, through cost-efficient external academic and industry collaborations. TG01 targets RAS-mutated cancers and is being tested in two clinical trials in Norway and the USA. TG01 is a therapeutic peptide vaccine adjuvanted by STIMULON QS-21 licensed from Agenus Inc.